BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 12931214)

  • 1. Comprehensive analysis of gene alterations in acute megakaryoblastic leukemia of Down's syndrome.
    Hirose Y; Kudo K; Kiyoi H; Hayashi Y; Naoe T; Kojima S
    Leukemia; 2003 Nov; 17(11):2250-2. PubMed ID: 12931214
    [No Abstract]   [Full Text] [Related]  

  • 2. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.
    Wechsler J; Greene M; McDevitt MA; Anastasi J; Karp JE; Le Beau MM; Crispino JD
    Nat Genet; 2002 Sep; 32(1):148-52. PubMed ID: 12172547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GATA1--a player in normal and leukemic megakaryopoiesis.
    Hitzler JK
    Pediatr Res; 2002 Dec; 52(6):831. PubMed ID: 12438656
    [No Abstract]   [Full Text] [Related]  

  • 4. A leukemogenic twist for GATA1.
    Look AT
    Nat Genet; 2002 Sep; 32(1):83-4. PubMed ID: 12172549
    [No Abstract]   [Full Text] [Related]  

  • 5. Origins of leukaemia in children with Down syndrome.
    Hitzler JK; Zipursky A
    Nat Rev Cancer; 2005 Jan; 5(1):11-20. PubMed ID: 15630411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tetrasomy 21 transient leukemia with a GATA1 mutation in a phenotypically normal trisomy 21 mosaic infant: case report and review of the literature.
    Sandoval C; Pine SR; Guo Q; Sastry S; Stewart J; Kronn D; Jayabose S
    Pediatr Blood Cancer; 2005 Jan; 44(1):85-91. PubMed ID: 15390279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Megakaryoblastic leukemia and Down's syndrome: a review.
    Zipursky A; Peeters M; Poon A
    Pediatr Hematol Oncol; 1987; 4(3):211-30. PubMed ID: 2978961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High leukaemia cure rate in Down's syndrome explained.
    Bradbury J
    Lancet Oncol; 2005 Mar; 6(3):134. PubMed ID: 15759357
    [No Abstract]   [Full Text] [Related]  

  • 9. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
    Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
    Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome.
    Taub JW; Mundschau G; Ge Y; Poulik JM; Qureshi F; Jensen T; James SJ; Matherly LH; Wechsler J; Crispino JD
    Blood; 2004 Sep; 104(5):1588-9. PubMed ID: 15317736
    [No Abstract]   [Full Text] [Related]  

  • 11. Transient leukaemia in newborn infants with trisomy 21.
    Kwong YL
    Br J Haematol; 2003 Aug; 122(4):686-7. PubMed ID: 12899726
    [No Abstract]   [Full Text] [Related]  

  • 12. The GATA1 mutation in an adult patient with acute megakaryoblastic leukemia not accompanying Down syndrome.
    Harigae H; Xu G; Sugawara T; Ishikawa I; Toki T; Ito E
    Blood; 2004 Apr; 103(8):3242-3. PubMed ID: 15070711
    [No Abstract]   [Full Text] [Related]  

  • 13. High incidence of CALM-AF10 fusion and the identification of a novel fusion transcript in acute megakaryoblastic leukemia in children without Down's syndrome.
    Abdelhaleem M; Beimnet K; Kirby-Allen M; Naqvi A; Hitzler J; Shago M
    Leukemia; 2007 Feb; 21(2):352-3. PubMed ID: 17170719
    [No Abstract]   [Full Text] [Related]  

  • 14. GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia.
    Crispino JD
    Pediatr Blood Cancer; 2005 Jan; 44(1):40-4. PubMed ID: 15390312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia.
    Ge Y; Stout ML; Tatman DA; Jensen TL; Buck S; Thomas RL; Ravindranath Y; Matherly LH; Taub JW
    J Natl Cancer Inst; 2005 Feb; 97(3):226-31. PubMed ID: 15687366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome.
    Klusmann JH; Reinhardt D; Hasle H; Kaspers GJ; Creutzig U; Hahlen K; van den Heuvel-Eibrink MM; Zwaan CM
    Leukemia; 2007 Jul; 21(7):1584-7. PubMed ID: 17443226
    [No Abstract]   [Full Text] [Related]  

  • 17. Expression of erythroid-specific genes in megakaryoblastic disorders.
    Ito E; Kasai M; Toki T; Arai K; Yokoyama M
    Leuk Lymphoma; 1996 Nov; 23(5-6):545-50. PubMed ID: 9031085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of erythroid-specific genes in acute megakaryoblastic leukaemia and transient myeloproliferative disorder in Down's syndrome.
    Ito E; Kasai M; Hayashi Y; Toki T; Arai K; Yokoyama S; Kato K; Tachibana N; Yamamoto M; Yokoyama M
    Br J Haematol; 1995 Jul; 90(3):607-14. PubMed ID: 7647001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder.
    Groet J; McElwaine S; Spinelli M; Rinaldi A; Burtscher I; Mulligan C; Mensah A; Cavani S; Dagna-Bricarelli F; Basso G; Cotter FE; Nizetic D
    Lancet; 2003 May; 361(9369):1617-20. PubMed ID: 12747884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acute megakaryoblastic leukemia in Down's syndrome following refractory anemia with excess of blasts].
    Hayashi Y; Habu Y; Fujii Y; Hanada R; Yamamoto K; Nishida T; Eguchi M
    Rinsho Ketsueki; 1986 Sep; 27(9):1650-5. PubMed ID: 2949094
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.